Cost-Effectiveness Analysis of Multiplex PCR with Magnetic Resonance Detection versus Empiric or Blood Culture-Directed Therapy for Management of Suspected Candidemia

Journal of Clinical Microbiology

Volumn 54, Issue 3, 2016, Pages 718-726

  Walker, Brandon ^a   Powers Fletcher, Margaret V ^b   Schmidt, Robert L ^a,b   Hanson, Kimberly E ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; FUNGAL DETECTION; HEALTH CARE COST; HOSPITAL COST; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PICHIA KUDRIAVZEVII; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL RATE; UNNECESSARY PROCEDURE; CANDIDA; CLASSIFICATION; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; GENETICS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TIME FACTOR;

ANTIFUNGAL AGENTS; BLOOD CULTURE; CANDIDA; CANDIDEMIA; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HUMANS; MAGNETIC RESONANCE IMAGING; MODELS, STATISTICAL; MULTIPLEX POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84959464742     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02971-15     Document Type: Article

References (44)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in U.S. hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317. http://dx.doi.org/10.1086/421946.
2. Falagas ME, Apostolou KE, Pappas VD. 2006. Attributable mortality of candidemia: A systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25:419-425. http://dx.doi.org/10.1007/s10096-006-0159-2.
3. Morrell M, Fraser VJ, Kollef MH. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640-3645. http://dx.doi.org/10.1128/AAC .49.9.3640-3645.2005.
4. Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, Kothari S, Kollef MH. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368.
5. Labelle AJ, Micek ST, Roubinian N, Kollef MH. 2008. Treatmentrelated risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 36:2967-2972. http://dx.doi.org/10.1097/CCM.0b0 13e31818b3477.
6. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
7. Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. 2013. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 57:3528-3535. http://dx.doi.org/10.1128/AAC.00136-13.
8. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. 2014. FKS mutant Candida glabrata: Risk factors and outcomes in patients with candidemia. Clin Infect Dis 59:819-825. http://dx.doi.org/10.1093/cid/ciu407.
9. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 48:2373-2380. http://dx.doi.org/10.1128/JCM.02390-09.
10. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
11. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre Y-M, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. 2015. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial. Clin Infect Dis 60:892-899. http://dx.doi.org/10.1093/cid/ciu959.
12. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, Wood C, Sobel JD. 2011. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 54:46-51. http://dx.doi.org/10.1111/j.1439-0507 .2009.01756.x.
13. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. 2007. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26:271-276. http://dx.doi.org/10.1007/s10096-007-0270-z.
14. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 43: 25-31. http://dx.doi.org/10.1086/504810.
15. Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. 2011. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 38:65-69. http://dx.doi.org/10.1016/j.ijantimicag.2011.02.016.
16. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller TM. 2012. Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 55:1352-1361. http://dx.doi.org/10.1093/cid/cis697.
17. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. 2009. Treatment of candidemia and invasive candidiasis in the intensive care unit: Post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 13:R159. http://dx.doi.org/10.1186/cc8117.
18. Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, Shorr AF. 2010. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study. BMC Infect Dis 10:150.
19. Moran C, Grussemeyer CA, Spalding JR, Benjamin DK, Jr, Reed SD. 2010. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control 38:78-80. http://dx.doi.org/10.1016/j.ajic.2009.06.014.
20. Heimann S, Cornely O, Wisplinghoff H, Kochanek M, Stippel D, Padosch S, Langebartels G, Reuter H, Reiner M, Vierzig A, Seifert H, Vehreschild MJ, Glossmann J, Franke B, Vehreschild JJ. 2014. Candidemia in the intensive care unit: Analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. Eur J Clin Microbiol Infect Dis 34:331-338.
21. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883-893. http://dx.doi.org/10.1086/520980.
22. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, Micafungin Invasive Candidiasis Working Group. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 369:1519-1527. http://dx.doi.org/10.1016/S0140-6736(07)60605-9.
23. Altun O, Almuhayawi M, Ullberg M, Ozenci V. 2013. Clinical evaluation of the FilmArray blood culture identification panel in identification of bacteria and yeasts from positive blood culture bottles. J Clin Microbiol 51:4130-4136. http://dx.doi.org/10.1128/JCM.01835-13.
24. Stone NR, Gorton RL, Barker K, Ramnarain P, Kibbler CC. 2013. Evaluation of PNA-FISH yeast traffic light for rapid identification of yeast directly from positive blood cultures and assessment of clinical impact. J Clin Microbiol 51:1301-1302. http://dx.doi.org/10.1128/JCM.00028-13.
25. Hall L, Le Febre KM, Deml SM, Wohlfiel SL, Wengenack NL. 2012. Evaluation of the Yeast Traffic LightPNAFISH probes for identification of Candida species from positive blood cultures. J Clin Microbiol 50:1446-1448. http://dx.doi.org/10.1128/JCM.06148-11.
26. Castanheira M, Messer SA, Jones RN, Farrell DJ, Pfaller MA. 2014. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int J Antimicrob Agents 44:320-326. http://dx.doi.org/10.1016/j.ijantimicag.2014.06.007.
27. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: Application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 51:2571-2581. http://dx.doi.org/10.1128/JCM .00308-13.
28. Reboli AC, Rotstein C, Kett DH, Maschio M, Cartier S, Chambers R, Tarallo M. 2011. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis. Pharmacoeconomics 29:705-717. http://dx.doi.org/10.2165/11584810-000000000-00000.
29. U.S. Department of Veterans Affairs. 2016. National Acquisition Center: Pharmaceutical catalog search. U.S. Department of Veterans Affairs, Washington, DC. http://www1.va.gov/nac/index.cfm?template-Search-Pharmaceutical-Catalog.
30. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. 2005. Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, Oxford, United Kingdom.
31. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. 2007. Invasive candidiasis treated in the intensive care unit: Observations from a randomized clinical trial. J Crit Care 22:237-244. http://dx.doi.org/10.1016/j.jcrc.2006.11.004.
32. Briggs A, Claxton K, Sculpher M. 2006. Decision modelling for health economic evaluation. Oxford University Press, Oxford, United Kingdom.
33. Pfaller MA. 2012. Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. Am J Med 125:S3-S13. http://dx.doi.org/10.1016/j.amjmed.2011.11.001.
34. Bilir SP, Ferrufino CP, Pfaller MA, Munakata J. 2015. The economic impact of rapid Candida species identification by T2Candida among highrisk patients. Future Microbiol 29:1-12. http://dx.doi.org/10.2217/fmb15.
35. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: Data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004-2008. Diagn Microbiol Infect Dis 74:323-331. http://dx.doi.org/10.1016/j.diagmicrobio.2012.10.003.
36. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 60:613-618. http://dx.doi.org/10.1093/jac/dkm212.
37. Schuster MG, Edwards JE, Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. 2008. Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med 149:83-90. http://dx.doi.org/10.7326/0003-4819-149-2-200807150-00004.
38. Blot S, Dimopoulos G, Rello J, Vogelaers D. 2008. Is Candida really a threat in the ICU? Curr Opin Crit Care 14:600-604. http://dx.doi.org/10.1097/MCC.0b013e32830f1dff.
39. Clancy CJ, Nguyen MH. 2013. Finding the "missing 50%" of invasive candidiasis: How nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284-1292. http://dx.doi.org/10.1093/cid/cit006.
40. Lee W, Liew Y, Chlebicki MP, Ong S, Lee P, Kwa A.2014. An observational study on early empiric versus culture-directed antifungal therapy in critically ill with intra-abdominal sepsis. Crit Care Res Pract 2014:479413. http://dx.doi.org/10.1155/2014/479413.
41. Fernandez J, Erstad BL, Petty W, Nix DE. 2009. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis 64:402-407. http://dx.doi.org/10.1016/j.diagmicrobio.2009.04 .002.
42. Cobos-Trigueros N, Kaasch AJ, Soriano A, Torres JL, Vergara A, Morata L, Zboromyrska Y, De La Calle C, Alejo I, Hernandez C, Cardozo C, Marco F, Del Rio A, Almela M, Mensa J, Martinez JA. 2014. Time to positivity and detection of growth in anaerobic blood culture vials predict the presence of Candida glabrata in candidemia: A two-center European cohort study. J Clin Microbiol 52:3082-3084. http://dx.doi.org/10.1128/JCM.01198-14.
43. Lai CC, Wang CY, Liu WL, Huang YT, Hsueh PR. 2012. Time to positivity of blood cultures of different Candida species causing fungaemia. J Med Microbiol 61:701-704. http://dx.doi.org/10.1099/jmm.0.038166-0.
44. Nawrot U, Kowalska-Krochmal B, Sulik-Tyszka B, Kozak M,͆wietek K, Pajaczkowska M, Piatkowska E, Rosiak D, Swoboda-Kopeć E. 2015. Evaluation of blood culture media for the detection of fungi. Eur J Clin Microbiol Infect Dis 34:161-167. http://dx.doi.org/10.1007/s10096-014-2218-4.